Surgery for gastrointestinal stromal tumors

• Verfasst von: Ronellenfitsch, Ulrich [VerfasserIn]
• Verfasst von: Hohenberger, Peter [VerfasserIn]
• Titel: Surgery for gastrointestinal stromal tumors
• Titelzusatz: state of the art of laparoscopic resection and surgery for M1 tumors
• Verf.angabe: Ulrich Ronellenfitsch, Peter Hohenberger
• E-Jahr: 2018
• Jahr: October 3, 2018
• Umfang: 8 S.
• Fussnoten: Gesehen am 11.04.2019
• Titel Quelle: Enthalten in: Visceral medicine
• Ort Quelle: Basel : Karger, 2016
• Jahr Quelle: 2018
• Band/Heft Quelle: 34(2018), 5, Seite 367-374
• ISSN Quelle: 2297-475X
• DOI: doi:10.1159/000491799
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1663154368

Abstract

Background: The principles of surgery for primary gastrointestinal stromal tumor (GIST) are resection with clear margins without lymphadenectomy, thus enabling organ-preserving resection in many cases. Tumor rupture needs to be avoided, because it entails peritoneal sarcomatosis. Given these preconditions, there is a rationale for laparoscopic resection of primary GIST. In metastatic GIST, surgery cannot achieve cure, but constitutes an important cornerstone of treatment. Resection can be performed either for residual lesions in responding patients, for focally progressive lesions, or as palliative measure in generalized progression. Methods: Selective literature review. Results: There is ample evidence on laparoscopic resection of gastric GIST, but none from randomized trials. The studies show favorable perioperative outcomes and suggest adequate oncological results; however, a direct comparison to open resection is difficult. For surgery in M1 stages, survival outcomes are better for resection in generalized response than in focal progression. Perioperative morbidity is acceptable. Surgery in generalized progression does not prolong survival and bears relevant morbidity risks. Conclusion: Laparoscopy seems an adequate surgical approach for primary gastric GIST, as long as the surgical principles relevant for this entity are respected. For other tumor sites, there is no sufficient evidence available. In M1 stages, selected patients may benefit from surgery. Survival differences between resection at different stages probably mirror the biology of the disease rather than the effect of the timing of the operation.